Skip to main content
. Author manuscript; available in PMC: 2019 Oct 2.
Published in final edited form as: Clin Cancer Res. 2019 Jul 12;25(19):5832–5842. doi: 10.1158/1078-0432.CCR-18-4049

Figure 2.

Figure 2.

Co-occurring somatic genomic alterations detected in the cfDNA of 170 patients with advanced solid tumors harboring an activating RET mutation, by pathway and RET alteration type (KIF5B-RET fusion, fusion involving partner other than KIF5B, and RET missense SNVs). Proportions are calculated by counting the number of patients with at least one sample containing an alteration of one or more genes in the pathway (see also Supplementary Fig. S3).